NCT04302103View on ClinicalTrials.gov

A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

January 14, 2022

Study Completion Date

February 11, 2022

Conditions

Systemic Myasthenia Gravis

Interventions

BIOLOGICAL

RC18 160mg

subcutaneous injection

BIOLOGICAL

RC18 240 mg

subcutaneous injection

Trial Locations (1)

100070

Beijing Tiantan Hospital,Capital Medical University, Beijing

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY

NCT04302103 - A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis | Biotech Hunter | Biotech Hunter